Phase II Study of Bexarotene in Patients With Acute Myeloid Leukemia

Summary

The purpose of this study is to evaluate the activity of bexarotene, a retinoic acid class drug, in patients with Acute Myeloid Leukemia (AML) that has returned after or is resistant to standard chemotherapy or are otherwise not eligible for conventional chemotherapy. Retinoic acids are a class of drugs related to Vitamin A, and have a wide range of effects within normal and malignant cells that affect cell growth and cell death.

Timeline

Start

2010-05-25

Primary completion

2013-10-01

Completion

2013-11-08

Drugs

Indications